Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,053 matching trials from the live ClinicalTrials.gov search.
Conditions
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Recurrent Brain Neoplasm, Recurrent Glioblastoma, Recurrent Malignant Glioma
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, STAT3 Inhibitor WP1066
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Malignant Brain Neoplasm, Resectable Brain Neoplasm
Interventions
Ad-hCMV-Flt3L, Ad-hCMV-TK, Biospecimen Collection, Magnetic Resonance Imaging, Survey Administration, Tumor Resection, Valacyclovir
Genetic · Procedure · Other + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
3 Years to 39 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult, Recurrent Glioblastoma, Astrocytoma, Malignant, Astrocytoma of Brain
Interventions
Re-resection, Temozolomide, Lomustine, Re-irradiation, Experimental therapy, Best supportive care
Procedure · Drug · Radiation + 1 more
Lead sponsor
Jasper Gerritsen
Other
Eligibility
18 Years to 90 Years
Enrollment
464 participants
Timeline
2023 – 2028
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Conditions
Malignant Glioma, Glioblastoma Multiforme, GBM, Astrocytoma, Oligodendroglioma
Interventions
131I-TM601
Drug
Lead sponsor
TransMolecular
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Grand Rapids, Michigan + 1 more
Conditions
Brain Metastases, Lung Cancer, Breast Cancer, Melanoma, Malignant Glioma
Interventions
2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks, 2B3-101 50 mg/m2 every 3 weeks
Drug
Lead sponsor
BBB-Therapeutics B.V.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Glioblastoma, Gliosarcoma
Interventions
3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy (IMRT), Temozolomide, Chloroquine, Tumor Treating Fields Therapy (TTF)
Radiation · Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Glioblastoma Multiforme, Gliosarcoma
Interventions
Tarceva, Temodar, Radiation Therapy
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
San Francisco, California
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, radiation therapy, stereotactic radiosurgery
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
217
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
Conditions
Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma
Interventions
Bevacizumab, Fludeoxyglucose F-18, Irinotecan Hydrochloride
Biological · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
11
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Conditions
Anaplastic Astrocytoma, Recurrent Anaplastic Astrocytoma
Interventions
Eflornithine, Lomustine
Drug
Lead sponsor
Orbus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more
Conditions
Brain and Central Nervous System Tumors
Interventions
fluorine F 18 fluorothymidine, positron emission tomography
Other · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Brain Tumors
Interventions
5-aminolevulinic acid
Drug
Lead sponsor
David W. Roberts
Other
Eligibility
21 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Brain and Central Nervous System Tumors
Interventions
lomustine, procarbazine hydrochloride, vincristine sulfate, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2018
U.S. locations
95
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Conditions
Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Glioma, Brain Neoplasm, Brain Cancer, Brain Tumor, Brain Tumor, Recurrent, Brain Neoplasm, Malignant
Interventions
Intra-arterial Cetuximab, Intra-arterial Mannitol, Hypofractionated re-irradiation
Drug · Radiation
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2036
U.S. locations
1
States / cities
New York, New York
Completed No phase listed Observational Accepts healthy volunteers

Clinical Development of MR Spectroscopy and Imaging in Brain Cancers

NCT02731521
Conditions
Malignant Gliomas, Astrocytomas, Oligodendrogliomas
Interventions
3 Tesla Scanning, 7 Tesla Scanning
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, paclitaxel, topotecan hydrochloride
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Glioma, Glioblastoma
Interventions
Focused ultrasound (FUS)
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Charlottesville, Virginia + 1 more
Conditions
Brain and Central Nervous System Tumors
Interventions
concurrent RAD001 10 mg/day, concurrent temozolomide, Radiation therapy, concurrent RAD001 2.5 mg/day, concurrent RAD001 5 mg/day, post-radiation RAD001 10 mg/day, post-radiation temozolomide
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
34
States / cities
Newark, Delaware • Gainesville, Florida • Jacksonville, Florida + 28 more
Conditions
Glioblastoma, MGMT-Unmethylated Glioblastoma
Interventions
Microtubule-Targeted Agent BAL101553, Radiation Therapy
Drug · Radiation
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 5 more
Conditions
Nausea, Vomiting, Glioma
Interventions
aprepitant, ondansetron
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Brain Stem Neoplasm, Pineal Region Neoplasm, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Recurrent Visual Pathway Glioma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, Refractory Visual Pathway Glioma
Interventions
Entinostat, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
Conditions
Malignant Neoplasms of Eye, Brain and Other Parts of Central Nervous System
Interventions
carmustine, radiation therapy, O6-Benzylguanine
Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
163
States / cities
Anchorage, Alaska • Phoenix, Arizona • Fairfield, California + 105 more
Conditions
Recurrent Adult Brain Tumor
Interventions
Gliadel wafers in combination with O6-benzylguanine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, carboplatin, temozolomide
Biological · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
Up to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York